Goldman Sachs Group Inc. increased its stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 48.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,664 shares of the biopharmaceutical company’s stock after buying an additional 13,863 shares during the period. Goldman Sachs Group Inc. owned approximately 0.13% of Bellicum Pharmaceuticals worth $526,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in shares of Bellicum Pharmaceuticals by 0.7% in the first quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock valued at $1,029,000 after buying an additional 610 shares during the period. American International Group Inc. increased its position in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 852 shares during the period. Bank of New York Mellon Corp increased its position in shares of Bellicum Pharmaceuticals by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 935 shares during the period. Teachers Advisors LLC increased its position in shares of Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 1,844 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Bellicum Pharmaceuticals by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,666 shares of the biopharmaceutical company’s stock valued at $910,000 after buying an additional 4,104 shares during the period. Institutional investors own 63.97% of the company’s stock.
Shares of Bellicum Pharmaceuticals, Inc. (BLCM) traded down 2.96% during mid-day trading on Monday, hitting $7.54. 170,688 shares of the company traded hands. The stock’s market capitalization is $250.52 million. Bellicum Pharmaceuticals, Inc. has a 1-year low of $7.41 and a 1-year high of $23.11. The firm’s 50 day moving average price is $10.61 and its 200-day moving average price is $12.15.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. On average, equities research analysts forecast that Bellicum Pharmaceuticals, Inc. will post ($3.00) EPS for the current year.
Several brokerages have recently issued reports on BLCM. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Ladenburg Thalmann Financial Services set a $31.00 price objective on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 24th. Raymond James Financial, Inc. reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. ValuEngine cut shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price objective (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Bellicum Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $26.20.
In other Bellicum Pharmaceuticals news, VP Ken Moseley sold 13,823 shares of the business’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the transaction, the vice president now owns 14,314 shares in the company, valued at $175,489.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David M. Spencer sold 10,000 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. Insiders sold 30,571 shares of company stock worth $367,295 in the last 90 days. Corporate insiders own 23.30% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
